{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T13:01:39Z","timestamp":1791896499853,"version":"4.3.4"},"publisher-location":"Chichester, UK","reference-count":59,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd003188","type":"reference-entry","created":{"date-parts":[[2003,11,20]],"date-time":"2003-11-20T22:18:21Z","timestamp":1069366701000},"source":"Crossref","is-referenced-by-count":53,"title":["Bisphosphonates in multiple myeloma"],"prefix":"10.1002","author":[{"given":"Benjamin","family":"Djulbegovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamish","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otavio Augusto Camara","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Bos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Glasmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2002,10,21]]},"reference":[{"key":"10.1002\/14651858.CD003188-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188-BIB3|cit2","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events","volume":"16","author":"Berenson","year":"1998","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188-BIB2|cit3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB4|cit4","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"European Journal of Hematology"},{"key":"10.1002\/14651858.CD003188-BIB5|cit5","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1046\/j.1365-2141.1998.00695.x","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma : a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB6|cit6","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate results of a multicentre double-blind study","volume":"2","author":"Daragon","year":"1993","journal-title":"European Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB7|cit7","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","article-title":"Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma","volume":"4","author":"Delmas","year":"1982","journal-title":"Metabolic Bone Disease and Related Research"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003188-BIB8|cit8","first-page":"106a","article-title":"Effects of intravenous ibandronate therapy on skeletal related events (SRE) and survival in patients with advanced multiple myeloma","volume":"92","author":"Fontana","year":"1998","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003188-BIB9|cit9","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01697625","article-title":"Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications","volume":"66","author":"Clemens","year":"1993","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD003188-BIB10|cit10","first-page":"439","article-title":"Prospective randomized trial of dichloromethilene bisphosphonate (clodronate) in patients with multiple myeloma","volume":"18","author":"Heim","year":"1995","journal-title":"Onkologie"},{"key":"10.1002\/14651858.CD003188-BIB11|cit11","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1: The results of the 12 months of pamidronate therapy","volume":"57 (suppl 1)","author":"Kraj","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"10.1002\/14651858.CD003188-BIB12|cit12","first-page":"379","article-title":"The effect of long-term pamidronate treatment on skeletal morbidity in advanced multiple myeloma","volume":"31","author":"Kraj","year":"2000","journal-title":"Acta Haematologica Polonica"},{"key":"10.1002\/14651858.CD003188-BIB13|cit13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomized, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003188-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomised trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB15|cit15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Hematology"},{"key":"10.1002\/14651858.CD003188-BIB16|cit16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB17|cit17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0609.1998.tb01073.x","article-title":"Long-term oral pamidronate treatment inhibits osteoclastic bone resorption andbone turnover without affecting osteoblastic function in multiple myeloma","volume":"61","author":"Abildgaard","year":"1998","journal-title":"European Journal of Hematology"},{"key":"10.1002\/14651858.CD003188-BIB18|cit18","first-page":"379","article-title":"Effect of clodronate on bone density of patients in multiple myeloma-2 year study","volume":"42","author":"Adam","year":"1996","journal-title":"Vnitr Lek"},{"key":"10.1002\/14651858.CD003188-BIB19|cit19","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB20|cit20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF01697625","article-title":"Multiple myeloma: effect of daily dichloromethelene bisphosphonate on skeletal complications","volume":"66","author":"Clements","year":"1993","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD003188-BIB21|cit21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM197206152862402","article-title":"Ineffectiveness of fluoride therapy in multiple myeloma","volume":"286","author":"Harley","year":"1972","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB22|cit22","first-page":"113","article-title":"Effect of pamidronate on skeletal morbidity in myelomatosis. Part 1. The results of the first 12 months of pamidronate therapy","volume":"57 (suppl 1)","author":"Kraj","year":"2000","journal-title":"Acta Poloniae Pharmaceutica"},{"key":"10.1002\/14651858.CD003188-BIB23|cit23","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/1097-0142(19800401)45:7<1669::AID-CNCR2820450724>3.0.CO;2-5","article-title":"Effect of sodium fluoride, calcium carbonate and vitamin D on the skeleton in multiple myeloma","volume":"45","author":"Kyle","year":"1980","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003188-BIB24|cit24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma","volume":"100","author":"McCloskey","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB25|cit25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hon.2900080104","article-title":"Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy","volume":"8","author":"Merlini","year":"1990","journal-title":"Hematology Oncology"},{"key":"10.1002\/14651858.CD003188-BIB26|cit26","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0959-8049(96)00228-6","article-title":"Pyridinium cross-links in multiple myeloma: correlation with clinical parameters and use for monitoring of intravenous clodronate therapy-a pilot study of the German Myeloma Treatment Group (GMTG)","volume":"32A","author":"Peest","year":"1996","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003188-BIB27|cit27","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1056\/NEJM198002073020602","article-title":"Effect of dichloromethylene diphosphonate on Skeletal Mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB28|cit28","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/jor.1100120518","article-title":"Effect of intermittent administration of pamidronate on the mechanical proprieties of canine cortical and trabecular bone","volume":"12","author":"Acito","year":"1994","journal-title":"Journal of Orthopedic Research"},{"key":"10.1002\/14651858.CD003188-BIB29|cit29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1056\/NEJM199402173300709","article-title":"The treatment of multiple myeloma","volume":"330","author":"Alexanian","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB30|cit30","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/sj.leu.2400892","article-title":"In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates","volume":"12","author":"Aparicio","year":"1998","journal-title":"Leukemia"},{"key":"10.1002\/14651858.CD003188-BIB31|cit31","first-page":"195","article-title":"The efficacy of pamidronate disodium in the treatment of osteolytic lesions and bone pain in multiple myeloma","volume":"9","author":"Berenson","year":"1998","journal-title":"Reviews in Contemporary Pharmacotherapy"},{"key":"10.1002\/14651858.CD003188-BIB32|cit32","first-page":"575A","article-title":"Double-blind placebo-controlled trial of intravenous ibandronate in breast cancer metastatic to bone","volume":"18","author":"Body","year":"1999","journal-title":"Proceedings of ASCO"},{"key":"10.1002\/14651858.CD003188-BIB33|cit33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1002\/sim.4780120517","article-title":"Interim analyses, stopping rules and data monitoring in clinical trials in Europe","volume":"2","author":"Buyse","year":"1993","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003188-BIB34|cit34","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1590\/S1516-31801997000300004","article-title":"Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature Database (LILACS)","volume":"115","author":"Castro","year":"1997","journal-title":"Revista paulista de medicina"},{"key":"10.1002\/14651858.CD003188-BIB35|cit35","article-title":"Ibandronate decreases bone disease development and osteoclast stimulatory activity in an in vivo model of human myeloma","volume":"In Press","author":"Cruz","year":"2001","journal-title":"Experimental Hematology"},{"key":"10.1002\/14651858.CD003188-BIB36|cit36","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1046\/j.1365-2141.1998.00976.x","article-title":"Anti-myeloma activity of pamidronate in vivo","volume":"103","author":"Dhodapkar","year":"1998","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systemic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD003188-BIB38|cit38","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB39|cit39","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003188-BIB40|cit40","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/BF01625440","article-title":"Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis","volume":"1","author":"Fromm","year":"1991","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003188-BIB41|cit41","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/jbmr.5650090521","article-title":"Preclinical pharmacology of CGP 42446, a new, potent heterocyclic biphosphonate compound","volume":"9","author":"Green","year":"1994","journal-title":"Journal of Bone Mineral Research"},{"key":"10.1002\/14651858.CD003188-BIB42|cit42","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.1992.10.1.134","article-title":"Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia","volume":"10","author":"Gucalp","year":"1992","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188-BIB43|cit43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"key":"10.1002\/14651858.CD003188-BIB44|cit44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD003188-BIB45|cit45","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1177\/106002809202601015","article-title":"Pamidronate","volume":"26","author":"Kellihan","journal-title":"Annals of Pharmacotherapy"},{"key":"10.1002\/14651858.CD003188-BIB46|cit46","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJM198806303182605","article-title":"An assessment of clinically useful measures of the consequences of treatment","volume":"318","author":"Laupacis","year":"1988","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD003188-BIB47|cit47","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF01622190","article-title":"Pamidronate: an unrecognized problem in gastrointestinal tolerability","volume":"4","author":"Lufkin","year":"1994","journal-title":"Osteoporosis International"},{"key":"10.1002\/14651858.CD003188-BIB48|cit48","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analysis?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003188-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3120","article-title":"Assessing the quality of reports of randomized trials: implications for the conduct of meta-analyses","volume":"3","author":"Moher","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD003188-BIB50|cit50","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD003188-BIB51|cit51","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1182\/blood.V96.2.381","article-title":"Introduction: the evolving role of bisphosphonate therapy in multiple myeloma","volume":"96","author":"Raje","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003188-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(89)91791-1","article-title":"Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia","volume":"2","author":"Ralston","year":"1989","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003188-BIB53|cit53","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/bjc.1997.48","article-title":"Dose-response study of ibandronate in the treatment of cancer-associated hypercalcemia","volume":"75","author":"Ralston","year":"1997","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD003188-BIB54|cit54","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1002\/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L","article-title":"Cellular and molecular mechanisms of action of bisphosphonates","volume":"88","author":"Rogers","year":"2000","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003188-BIB55|cit55","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003188-BIB56|cit56","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias, dimension of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association (JAMA)"},{"key":"10.1002\/14651858.CD003188-BIB57|cit57","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF02405012","article-title":"Structure-activity relationships of various bisphosphonates","volume":"35","author":"Shinoda","year":"1983","journal-title":"Calcified Tissue International"},{"key":"10.1002\/14651858.CD003188-BIB58|cit58","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2141.1997.2713086.x","volume":"98","author":"Shipman","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003188-BIB59|cit59","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/9780470693926.ch11","article-title":"Investigating and dealing with publication and other biases","volume-title":"Systematic reviews in health care. Meta-analysis in the context","author":"Sterne","year":"2001"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD003188\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:17:12Z","timestamp":1628529432000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003188"}},"subtitle":[],"editor":[{"given":"Benjamin","family":"Djulbegovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2002,10,21]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003188","relation":{},"subject":[],"published":{"date-parts":[[2002,10,21]]}}}